A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With RAEB-1 AND RAEB-2 Myelodysplastic Syndrome (MDS) and AML With Trisomy 8
The myelodysplastic syndromes (MDS) and acute myelogenous leukemias (AML) are a group of
heterogeneous diseases with wide variation in clinical presentation and disease severity.
Typically patients are older adults with co-morbidities. AML and MDS are characterized by
variable degrees of cytopenias (anemia, neutropenia, thrombocytopenia) due to ineffective
hematopoiesis and dysplastic bone marrow morphology or hematological malignancy.
Treatment of MDS is unsatisfactory: chemotherapy has a limited role in the management of
leukemic progression; autologous stem cell transplantation does not prolong relapse-free
survival and stem cell transplantation is poorly tolerated in older individuals. Some MDS
patients have been shown to respond to a wide variety of immunosuppressive agents ranging
from corticosteroids to cyclosporine (CsA) and horse antithymocyte globulin (h-ATG).
However, the overall response rate is less than 30% and relapse continues to be a problem.
Few treatments appear to change the natural history of MDS however, growth factors,
decitabine, and lenalidomide can improve cytopenias, and 5-azacytidine, can reduce
transfusion requirements, and improve quality of life when compared to supportive care. In
addition most MDS patients are older and tolerate aggressive therapies poorly.
Some AML patients can be cured with chemotherapy or by allogeneic stem cell transplantation.
However standard treatment approaches are not effective for patients who become refractory
to chemotherapy, elderly patients, and those who relapse after transplantation.
The management of MDS and relapsed/refractory AML patients therefore remains unsatisfactory
and targeted therapies are needed. One such investigational drug, ON 01910.Na, is a potent
inhibitor of cyclin D1 and mitosis. ON01910.Na shows activity against a broad spectrum of
tumor cell lines. Animal model studies show little toxicity with a high therapeutic index
in these tumors. In addition, the fact that MDS bone marrow (particularly trisomy 8) and
patients with AML with the trisomy 8 abnormality (Sloand, unpublished data) over-express
cyclin D1 and in vitro studies have demonstrated activity against cytogenetically abnormal
cells and blasts despite minimal inhibition of normal hematopoiesis provides a rationale for
its use in select patients with MDS or AML.
We therefore propose a non-randomized, pilot, dose escalating Phase I study of ON 01910.Na
in MDS and patients with refractory AML with trisomy 8.
The primary objective is to determine the safety (including the maximum tolerated dose
and/or dosing regimen) of ON 01910.Na when administered in escalating doses in select
patients with MDS or AML and bone marrow RNA analysis to assess if gene expression can
predict clinical response to ON 01910.Na in subjects with MDS.
Secondary objectives include plasma pharmacokinetics and biological effects of ON 01910.Na
on cell-cycle pathways of MDS or AML cells, and bone marrow RNA analysis to assess if gene
expression can predict clinical response to ON 01910.Na in subjects with MDS.
The primary endpoint will be the toxicity profile at each dose level. Secondary endpoints
will include the evaluation of early evidence of disease response by blast and cytogenetic
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
The toxicity profile at each dose level.
Neal S Young, M.D.
National Heart, Lung, and Blood Institute (NHLBI)
United States: Federal Government
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Bethesda, Maryland 20892|